Provectus Biopharmaceuticals (PVCT) 10-Q 12 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 12, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-36457
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Entity Tax Identification Number	90-0031917
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	10025 Investment Drive
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	Knoxville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37932
City Area Code	866
Local Phone Number	594-5999
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		404,007,037

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 47,407	$ 97,231
Short-term receivables - legal fees, settlement and other, net	5,408	3,930
Prepaid expenses	294,406	322,518
Total Current Assets	347,221	423,679
Equipment and furnishings, less accumulated depreciation of $84,745 and $78,313, respectively	38,269	44,701
Operating lease right-of-use asset	80,809	120,821
Total Assets	466,299	589,201
Current Liabilities:
Accounts payable - trade	1,209,108	956,860
Other accrued expenses	1,653,506	1,500,782
Current portion of accrued interest		2,774,968
Current portion of accrued interest - related parties		1,766,493
Current portion of note payable	127,393	236,228
Current portion of convertible notes payable		16,622,000
Current portion of convertible notes payable - related parties		6,770,000
Current portion of operating lease liability	86,974	84,383
Total Current Liabilities	3,076,981	30,711,714
Note payable, non-current portion		39,061
Operating lease liability, non-current portion		44,783
Total Liabilities	3,076,981	30,795,558
Commitments and contingencies (Note 10)
Stockholders’ Deficiency:
Preferred stock, value
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 403,782,037 and 398,807,037 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	403,783	398,808
Additional paid-in capital	240,742,061	209,923,347
Accumulated other comprehensive loss	(34,381)	(34,097)
Accumulated deficit	(243,743,959)	(240,494,415)
Total Stockholders’ Deficiency	(2,610,682)	(30,206,357)
Total Liabilities and Stockholders’ Deficiency	466,299	589,201
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock, value	12,373
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock, value	$ 9,441

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Accumulated depreciation	$ 84,745	$ 78,313
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Preferred Stock, Shares Authorized		25,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	403,782,037	398,807,037
Common stock, shares outstanding	403,782,037	398,807,037
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		240,000
Preferred Stock, Shares Outstanding		100
Preferred Stock, Liquidation Preference Per Share		$ 3,500
Series D Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized	12,374,000	12,374,000
Preferred Stock, Shares Outstanding	12,373,247	0
Preferred Stock, Liquidation Preference Per Share	$ 14,164,889	$ 0
Preferred Stock, Shares Issued	12,373,247	0
Series D-1 Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized	9,441,000
Preferred Stock, Shares Outstanding	9,440,594	0
Preferred Stock, Liquidation Preference Per Share	$ 108,075,431	$ 0
Preferred Stock, Shares Issued	9,440,594	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating Expenses:
Research and development	$ 602,979	$ 696,454	$ 1,258,123	$ 1,605,900
General and administrative	619,038	514,394	1,144,570	1,053,188
Total Operating Expenses	1,222,017	1,210,848	2,402,693	2,659,088
Total Operating Loss	(1,222,017)	(1,210,848)	(2,402,693)	(2,659,088)
Other Income/(Expense):
EIDL grant		3,000		3,000
Research and development tax credit	32,144	113	32,144	26,364
Investment and interest income		3,334	1	3,413
Gain from extinguishment	63,094		63,094
Interest expense	(452,812)	(410,404)	(942,087)	(815,555)
Total Other Expense, Net	(357,574)	(403,957)	(846,848)	(782,778)
Net Loss	$ (1,579,591)	$ (1,614,805)	$ (3,249,541)	$ (3,441,866)
Basic and Diluted Loss Per Common Share	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	403,628,466	390,714,200	402,910,628	390,635,608

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Net Loss	$ (1,579,591)	$ (1,614,805)	$ (3,249,541)	$ (3,441,866)
Other Comprehensive Income (Loss):
Foreign currency translation adjustments	(1,121)	2,233	(34,381)	(30,802)
Total Comprehensive Loss	$ (1,580,712)	$ (1,612,572)	$ (3,283,922)	$ (3,472,668)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Series B Preferred Stock [Member]	Series D Preferred Stock [Member]	Series D-1 Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning Balance at Dec. 31, 2019				$ 389,889	$ 209,378,835	$ (24,008)	$ (233,816,828)	$ (24,072,112)
Beginning Balance, shares at Dec. 31, 2019	100			389,889,475
Common stock issued upon exercise of warrants				$ 800	41,840			42,640
Common stock issued upon exercise of warrants, shares				800,000
Comprehensive loss:
Net loss							(1,827,061)	(1,827,061)
Other comprehensive income (loss)						(9,027)		(9,027)
Ending Balance at Mar. 31, 2020				$ 390,689	209,420,675	(33,035)	(235,643,889)	(25,865,560)
Ending Balance, shares at Mar. 31, 2020	100			390,689,475
Beginning Balance at Dec. 31, 2019				$ 389,889	209,378,835	(24,008)	(233,816,828)	(24,072,112)
Beginning Balance, shares at Dec. 31, 2019	100			389,889,475
Comprehensive loss:
Net loss								(3,441,866)
Other comprehensive income (loss)								(30,802)
Ending Balance at Jun. 30, 2020				$ 390,714	209,421,800	(30,802)	(237,258,694)	(27,476,982)
Ending Balance, shares at Jun. 30, 2020	100			390,714,475
Beginning Balance at Mar. 31, 2020				$ 390,689	209,420,675	(33,035)	(235,643,889)	(25,865,560)
Beginning Balance, shares at Mar. 31, 2020	100			390,689,475
Common stock issued for services				$ 25	1,125			1,150
Common stock issued for services, shares				25,000
Comprehensive loss:
Net loss							(1,614,805)	(1,614,805)
Other comprehensive income (loss)						2,233		2,233
Ending Balance at Jun. 30, 2020				$ 390,714	209,421,800	(30,802)	(237,258,694)	(27,476,982)
Ending Balance, shares at Jun. 30, 2020	100			390,714,475
Beginning Balance at Dec. 31, 2020				$ 398,808	209,923,347	(34,097)	(240,494,415)	(30,206,357)
Beginning Balance, shares at Dec. 31, 2020	100			398,807,037
Common stock issued upon exercise of warrants				$ 4,500	235,350			239,850
Common stock issued upon exercise of warrants, shares				4,500,000
Stock-based compensation:
Common stock				$ 250	19,500			19,750
Common stock, shares				250,000
Comprehensive loss:
Net loss							(1,669,950)	(1,669,950)
Other comprehensive income (loss)						837		837
Ending Balance at Mar. 31, 2021				$ 403,558	210,178,197	(33,260)	(242,164,365)	(31,615,870)
Ending Balance, shares at Mar. 31, 2021	100			403,557,037
Beginning Balance at Dec. 31, 2020				$ 398,808	209,923,347	(34,097)	(240,494,415)	(30,206,357)
Beginning Balance, shares at Dec. 31, 2020	100			398,807,037
Comprehensive loss:
Net loss								(3,249,541)
Other comprehensive income (loss)								(34,381)
Ending Balance at Jun. 30, 2021		$ 12,373	$ 9,441	$ 403,783	240,742,061	(34,381)	(243,743,959)	(2,610,682)
Ending Balance, shares at Jun. 30, 2021	100	12,373,247	9,440,594	403,782,037
Beginning Balance at Mar. 31, 2021				$ 403,558	210,178,197	(33,260)	(242,164,365)	(31,615,870)
Beginning Balance, shares at Mar. 31, 2021	100			403,557,037
Common stock issued upon exercise of warrants				$ 200	10,460			10,660
Common stock issued upon exercise of warrants, shares				200,000
Common stock issued for services				$ 25	1,650			1,675
Common stock issued for services, shares				25,000
Comprehensive loss:
Net loss							(1,579,591)	(1,579,591)
Other comprehensive income (loss)						(1,121)		(1,121)
Warrants					488			488
Conversion of PRH Notes to Series D Preferred Stock		$ 12,373			3,528,849			3,541,222
Conversion of PRH notes to series D preferred stock, Shares		12,373,247
Conversion of PRH Notes to Series D-1 Preferred Stock			$ 9,441		27,022,417			27,031,858
Conversion of PRH notes to series D1 preferred stock, Shares			9,440,594
Ending Balance at Jun. 30, 2021		$ 12,373	$ 9,441	$ 403,783	$ 240,742,061	$ (34,381)	$ (243,743,959)	$ (2,610,682)
Ending Balance, shares at Jun. 30, 2021	100	12,373,247	9,440,594	403,782,037

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash Flows From Operating Activities:
Net loss	$ (3,249,541)	$ (3,441,866)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	21,913	1,150
Noncash lease expense	40,012	36,801
Depreciation	6,432	7,046
Amortization of patents		228,107
Forgiveness of PPP Loan	(62,500)
Changes in operating assets and liabilities
Short term receivables	(1,632)	47,653
Prepaid expenses	123,230	207,590
Accounts payable - trade	252,254	332,134
Loan payable	(85,398)
Other accrued expenses	152,786	120,817
Operating lease liability	(42,191)	(38,958)
Accrued interest expense	939,618	815,430
Net Cash Used In Operating Activities	(1,905,017)	(1,684,096)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	1,700,000	2,375,000
Proceeds from issuance of convertible notes payable - related parties		100,000
Repayment of short-term note payable	(95,387)
Proceeds from note payable		62,500
Proceeds from exercise of warrants	250,510	42,640
Net Cash Provided By Financing Activities	1,855,123	2,580,140
Effect of Exchange Rate Changes on Cash	70	(3,536)
Net (Decrease)/Increase In Cash and Cash Equivalents	(49,824)	892,508
Cash and Cash Equivalents, Beginning of Period	97,231	590,706
Cash and Cash Equivalents, End of Period	47,407	1,483,214
Cash paid during the period for:
Interest
Income taxes
Non-cash investing and financing activities:
Conversion of 2017 Notes and 2020 Notes to Convertible Preferred Stock Series D and D-1	30,560,080
Purchase of insurance policies financed by short-term note payable	$ (309,710)

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	1. Business Organization, Nature of Operations and Basis of Presentation Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases, with the aim of maximizing the curative impact of these medicines and achieving immunity from treated disease. These investigational drugs are based on an entire, wholly owned, family of small molecules called halogenated xanthenes (“HXs”). Our lead HX molecule is named rose bengal disodium (“RBD”). ● Oncology: ® Oral formulations of cGMP RBD are also undergoing preclinical study as prophylactic and therapeutic treatments for high-risk and refractory adult solid tumor cancers, such as head and neck, breast, colorectal, and testicular cancers. ● Pediatric Oncology: ● Hematology: ● Virology: ● Microbiology: ● Ophthalmology: ● Dermatology: ® ● Animal Health: To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2020 filed with the SEC on March 2, 2021. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. SARS-CoV-2 was reportedly first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at June 30, 2021. The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials; disrupt the Company’s regulatory activities; and/or have other adverse effects on the Company’s clinical development. Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares June 30, June 30, 2021 2020 Warrants 82,589,164 95,767,428 Options 4,800,000 2,800,000 Convertible preferred stock 21,813,941 65,663 Total potentially dilutive shares 109,203,105 98,633,091

Liquidity and Going Concern

Liquidity and Going Concern	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company’s cash and cash equivalents were $ 47,407 at June 30, 2021. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop PV-10, PH-10, and/or any other halogenated xanthene-based drug products, and to raise additional capital. The Company plans to access capital resources through possible public or private equity offerings, exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due. During the six months ended June 30, 2021, warrant holders exercised warrants to purchase an aggregate of 4,700,000 shares of common stock at a price of $ 0.0533 per share. In connection with these exercises, the Company received aggregate cash proceeds of $ 250,510 . On June 20, 2021, the outstanding non-amended 2017 Notes converted into 12,373,247 .2862 9,440,594 2.862 30,560,080 The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company, or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2021 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

Critical Accounting Policies

Critical Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Critical Accounting Policies	3. Critical Accounting Policies Since the date the Company’s December 31, 2020 consolidated financial statements were issued in its 2020 Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below. Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes Convertible Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with ASC Topic 815: Derivatives and Hedging If the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the commitment date fair value to the effective conversion price of the instrument. Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ deficiency.

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Convertible Notes Payable	4. Convertible Notes Payable 2017 Financing On March 23, 2017, the Company entered into a 2017 Term Sheet with the PRH Group that set forth the terms on which the PRH Group would use their best efforts to arrange for a financing of a minimum of $ 10,000,000 and maximum of $ 20,000,000 (the “2017 Financing”). The 2017 Financing was in the form of a secured convertible loan from the PRH Group and other investors in the 2017 Financing, which were evidenced by secured convertible promissory notes (individually a “2017 Note” and collectively, the “2017 Notes”) from the Company to the PRH Group and other investors. As of June 30, 2021 and December 31, 2020, the Company had received aggregate proceeds of $ 20,067,000 from the issuance of the 2017 Notes, respectively, of which $ 6,770,000 was received from related parties. 2020 Financing On December 31, 2019, the Board approved a Definitive Financing Term Sheet (the “2020 Term Sheet”), which sets forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $ 20,000,000 (the “2020 Financing”). The 2020 Financing was in the form of secured convertible loans from investors that were evidenced by secured convertible promissory notes (the “2020 Notes”). The 2020 Term Sheet was similar to the 2017 Term Sheet. Subject to the terms and conditions of the 2020 Term Sheet, the Company used its best efforts to arrange for the 2020 Financing, which amounts were obtained in several tranches. As of June 30, 2021 and December 31, 2020, the Company had received proceeds of $ 5,025,000 and $ 3,325,000 in connection with the 2020 Financing, of which $ 100,000 was received from related parties. Firm Commitment Previously, the Company had not designated the Series D Preferred Stock into which the 2017 Notes and the 2020 Notes (collectively the “Notes”) were convertible into. As a result, the Company did not analyze the Notes for a potential beneficial conversion feature as the definition of a firm commitment had not been met since the Notes were not yet convertible. On June 17, 2021, the required Certificates of Designation were filed with the Delaware Secretary of State. Accordingly, a firm commitment was achieved. The Company analyzed the Notes for a beneficial conversion feature and determined that there was none because the Notes have an effective conversion price of $ 0.2862 2.862 0.07 The Series D and D-1 Convertible Preferred Stock The 2017 Notes originally provided that they were convertible into a new class of the Company’s preferred stock, $ 0.001 par value per share (“Preferred Stock”), at a price per share equal to $ 0.2862 (the “Original Conversion Price”), which would be convertible into one share (the “Original Conversion Ratio”) of the Company’s common stock, $0.001 par value per share (“Common Stock”). In order to ensure that the Company had sufficient authorized shares of Preferred Stock into which the 2017 Notes would convert, yet keep the economic terms of the 2017 Notes substantially equivalent, the Company entered into amendments (the “Amendments”) to the 2017 Notes (as amended, the “Amended 2017 Notes”) with a large majority of the holders of 2017 Notes to increase the conversion price by 10 times from $ 0.2862 2.862 (the “New Conversion Price”) and to change the conversion ratio by providing that one share of Preferred Stock would be convertible into 10 shares of Common Stock (the “New Conversion Ratio”). The impact of the Amendments was to reduce by 10 times the number of shares of Preferred Stock into which the 2017 Notes would convert, while keeping the economic terms the same by increasing the conversion ratio into Common Stock by 10 times. The 2020 Notes had substantially similar terms to the Amended 2017 Notes, including being convertible into Preferred Stock at the New Conversion Price, with the Preferred Stock being convertible into Common Stock at the New Conversion Ratio. In order to (i) address the fact that a small minority of the holders of 2017 Notes did not execute the Amendments and (ii) ensure economic fairness for all of the holders of the 2017 Notes and 2020 Notes, the Company designated two separate classes of Preferred Stock into which the 2017 Notes and 2020 Notes would convert: (i) the Company’s Series D Convertible Preferred Stock, par value $ 0.001 per share (the “Series D Convertible Preferred Stock”), was designated for the holders of 2017 Notes who did not execute the Amendments and (ii) the Company’s Series D-1 Convertible Preferred Stock, par value $ 0.001 per share (the “Series D-1 Convertible Preferred Stock”), was designated for the holders of Amended 2017 Notes (i.e., who did execute the Amendments) and the holders of the 2020 Notes. On June 20, 2021, the outstanding non-amended 2017 Notes converted into 12,373,247 shares of Series D Convertible Preferred Stock at the Original Conversion Price of $ 0.2862 9,440,594 shares of Series D-1 Convertible Preferred Stock at the New Conversion Price of $ 2.862 . As a result of the conversion of the 2017 Notes and 2020 Notes into convertible preferred stock, all the security interests of these notes in the Company’s intellectual property were released. The rights, preferences and privileges of the Series D Convertible Preferred Stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (the “Series D Certificate of Designation”). The rights, preferences and privileges of the Series D-1 Convertible Preferred Stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Certificate of Designation”). The Board of Directors of the Company approved each of the Series D Certificate of Designation and Series D-1 Certificate of Designation on June 16, 2021, and each of the Series D Certificate of Designation and Series D-1 Certificate of Designation were filed with the Delaware Secretary of State on June 17, 2021. The Series D Certificate of Designation and Series D-1 Certificate of Designation are the same, other than certain key differences to account solely for the different conversion ratios for the holders of 2017 Notes who did not execute Amendments compared to the holders of Amended 2017 Notes and the holders of 2020 Notes. Number of Shares The Series D Certificate of Designation established and designated 12,374,000 9,441,000 Rank The Series D Convertible Preferred Stock and the Series D-1 Convertible Preferred Stock rank pari passu pari passu Dividends The Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock do not have any dividend preference but are entitled to receive, on a pari passu Liquidation Preference Upon the occurrence of the liquidation, winding-up or dissolution of the Company or certain mergers, corporate reorganizations or sales of the Company’s assets (each, a “Company Event”), holders of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will be entitled to receive a liquidation preference before any distributions are made to holders of any other class or series of the Company’s capital stock junior to the Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock. If a Company Event occurs within two years of June 20, 2021 (the “Date of Issuance”), the holders of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will receive for each share of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock, respectively, an amount in cash equal to the Original Issue Price (as defined in the Series D Certificate of Designation and Series D-1 Certificate of Designation, respectively) multiplied by four. If a Company Event occurs from and after the second anniversary of the Date of Issuance, the holders of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will receive for each share of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock, respectively, an amount in cash equal to the Original Issue Price multiplied by six. The Original Issue Price for the Series D Convertible Preferred Stock is $ 0.2862 2.862 Voting Rights Holders of shares of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will vote together with the holders of Common Stock as a single class. Each share of Series D Convertible Preferred Stock carries the right to one vote per share. Each share of Series D-1 Convertible Preferred Stock carries the right to 10 votes per share. The Company is not permitted to amend, alter or repeal its Certificate of Incorporation or Bylaws in a manner adverse to the relative rights, preferences, qualifications, limitations or restrictions of the Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock without the affirmative vote of a majority of the votes entitled to be cast by holders of outstanding shares of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock, voting together as a single class with each share of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock having a number of votes equal to the number of shares of Common Stock then issuable upon conversion of such share of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock. Conversion The Series D Convertible Preferred Stock is convertible at the option of the holders thereof into shares of Common Stock based on a one-for-one conversion ratio. The Series D-1 Convertible Preferred Stock is convertible at the option of the holders thereof into shares of Common Stock based on a one-for-10 conversion ratio. The conversion ratio of the Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock is subject to adjustment for stock splits and combinations, recapitalizations, reclassifications, reorganizations, mergers and consolidations. The Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will automatically convert into shares of Common Stock upon the fifth anniversary of the Date of Issuance.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2021
Notes Payable [Abstract]
Notes Payable	5. Notes Payable On April 20, 2020, the Company received a $ 62,500 loan under the CARES Act PPP (the “PPP Loan”). The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower’s average monthly payroll expenses. On May 20, 2021, the Company applied for forgiveness of the PPP Loan. On June 2, 2021, the Company was awarded full forgiveness of the PPP Loan. The Company recognized a gain on forgiveness of note payable in the period in which it obtained forgiveness, and is included in gain from extinguishment on the accompanying condensed consolidated statements of operations. The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of June 30, 2021 and December 31, 2020, the balance of the note payable was $ 127,393 and $ 212,790 , respectively.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	6. Related Party Transactions During the three months ended June 30, 2021 and June 30, 2020, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $ 42,400 and $ 11,200 respectively, for services rendered. During the six months ended June 30, 2021 and June 30, 2020, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $ 127,200 and $ 63,600 , respectively, for services rendered. Accrued director fees for Mr. Horowitz as of June 30, 2021 and December 31, 2020 were $ 37,500 and $ 75,000 , respectively. Mr. Horowitz serves as both COO and a Director. See Note 4 for details of other related party transactions. Director fees during the three months ended June 30, 2021 and June 30, 2020 were $ 96,250 and $ 96,250 , respectively. Director fees during the six months ended June 30, 2021 and June 30, 2020 were $ 192,500 and $ 192,500 , respectively. Accrued directors’ fees as of June 30, 2021 and December 31, 2020 were $ 1,368,089 and $ 1,175,589 , respectively, and are included in other accrued expenses on the accompanying condensed consolidated balance sheet.

Short-term Receivables

Short-term Receivables	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
Short-term Receivables	7. Short-term Receivables The following table summarizes the receivables at June 30, 2021 and December 31, 2020: Summary of Short-term Receivables June 30, 2021 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 5,408 $ - $ - $ 5,408 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 5,408 $ - $ - $ 5,408 December 31, 2020 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 3,930 $ - $ - $ 3,930 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 3,930 $ - $ - $ 3,930

Stockholders_ Deficiency

Stockholders’ Deficiency	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Stockholders’ Deficiency	8. Stockholders’ Deficiency Common Stock During the six months ended June 30, 2021, the Company issued an aggregate of 250,000 shares of immediately vested restricted common stock with a grant date value of $ 19,750 for services. During the six months ended June 30, 2021, the Company issued an aggregate of 25,000 shares of immediately vested restricted common stock to an advisory board member with a grant date value of $ 1,675 for services. See also Note 11 – Subsequent Events. Preferred Stock On June 20, 2021, the Company issued 12,373,247 and 9,440,594 shares of Series D and D-1 Convertible Preferred Stock, respectively. See Note 4 convertible notes payable. Warrants During the six months ended June 30, 2021, warrant holders exercised warrants to purchase an aggregate of 4,700,000 shares of common stock at a price of $ 0.0533 per share. In connection with these exercises, the Company received aggregate cash proceeds of $ 250,510 . See Note 11 – Subsequent Events. During the six months ended June 30, 2021, the Company issued three-year immediately vested warrants to purchase an aggregate of 25,000 shares of common stock with an exercise price of $ 0.2862 per share to an advisory board member. The warrants had an issuance date fair value of an aggregate of $ 488 , which was recognized immediately and is included in general and administrative expenses on the condensed consolidated statements of operations.

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases
Leases	9. Leases The Company currently leases 4,500 square feet of corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of five years June 30, 2022 . Payments are approximately $ 7,900 per month. Total operating lease expense for the three months ended June 30, 2021 was $ 23,044 , of which, $ 15,363 was included within research and development and $ 7,681 was included within general and administrative expenses on the condensed consolidated statement of operations. Total operating lease expense for the three months ended June 30, 2020 was $ 22,332 of which, $ 14,888 was included within research and development and $ 7,444 was included within general and administrative expenses on the condensed consolidated statement of operations. Total operating lease expense for the six months ended June 30, 2021 was $ 47,806 , of which, $ 31,871 was included within research and development and $ 15,935 was included within general and administrative expenses on the condensed consolidated statement of operations. Total operating lease expense for the six months ended June 30, 2020 was $ 43,634 , of which, $ 29,090 was included within research and development and $ 14,544 was included within general and administrative expenses on the condensed consolidated statement of operations. As of June 30, 2021, the Company had no leases that were classified as a financing lease. As of June 30, 2021, the Company did not have additional operating and financing leases that have not yet commenced.  A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-Use Assets and Liabilities For The Six Months Ended June 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 45,784 $ 44,882 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 1.00 Year 2.00 Years Weighted Average Discount Rate Operating leases 8.0 % 8.0 % Future minimum payments under the Company’s non-cancellable lease obligations as of June 30, 2021 were as follows: Schedule of Future Minimum Payment for Lease Years Amount 2021 46,687 2022 $ 46,687 Total future minimum lease payments 93,374 Less: amount representing imputed interest (6,400 ) Total $ 86,974

Commitments, Contingencies and

Commitments, Contingencies and Litigation	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	10. Commitments, Contingencies and Litigation The Company may, from time to time, be involved in litigation arising in the ordinary course of business or which may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. Series D-1 Convertible Preferred Stock Subsequent to June 30, 2021, the Company received total investments of $ 150,000 from non-related party investors in exchange for an aggregate of 52,411 shares of restricted Series D-1 Convertible Preferred Stock that have not yet been issued. Common Stock Subsequent to June 30, 2021, the Company issued an aggregate of 25,000 shares of immediately vested restricted common stock to a consultant for services. Warrants Subsequent to June 30, 2021, warrant holders exercised warrants to purchase an aggregate of 200,000 shares of common stock at a price of $ 0.0533 per share.

Critical Accounting Policies (P

Critical Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes
Convertible Instruments	Convertible Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with ASC Topic 815: Derivatives and Hedging If the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the commitment date fair value to the effective conversion price of the instrument.
Preferred Stock	Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ deficiency.

Business Organization, Nature_2

Business Organization, Nature of Operations and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares June 30, June 30, 2021 2020 Warrants 82,589,164 95,767,428 Options 4,800,000 2,800,000 Convertible preferred stock 21,813,941 65,663 Total potentially dilutive shares 109,203,105 98,633,091

Short-term Receivables (Tables)

Short-term Receivables (Tables)	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
Summary of Short-term Receivables	The following table summarizes the receivables at June 30, 2021 and December 31, 2020: Summary of Short-term Receivables June 30, 2021 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 5,408 $ - $ - $ 5,408 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 5,408 $ - $ - $ 5,408 December 31, 2020 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 3,930 $ - $ - $ 3,930 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 3,930 $ - $ - $ 3,930

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases
Schedule of Right-of-Use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-Use Assets and Liabilities For The Six Months Ended June 30, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 45,784 $ 44,882 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 1.00 Year 2.00 Years Weighted Average Discount Rate Operating leases 8.0 % 8.0 %
Schedule of Future Minimum Payment for Lease	Future minimum payments under the Company’s non-cancellable lease obligations as of June 30, 2021 were as follows: Schedule of Future Minimum Payment for Lease Years Amount 2021 46,687 2022 $ 46,687 Total future minimum lease payments 93,374 Less: amount representing imputed interest (6,400 ) Total $ 86,974

Schedule of Securities Excluded

Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	109,203,105	98,633,091
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	82,589,164	95,767,428
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	4,800,000	2,800,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	21,813,941	65,663

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	Jun. 20, 2021	Jun. 30, 2021	Dec. 31, 2020
Stock-based compensation:
Cash and Cash Equivalents, at Carrying Value		$ 47,407	$ 97,231
Warrants to purhcase common stock		4,700,000
Common stock exercise price		$ 0.0533
Proceeds from Issuance of Warrants		$ 250,510
Non-Amended 2017 Notes [Member] | Series D Convertible Preferred Stock [Member] | Two Thousand And Twenty Notes [Member]
Stock-based compensation:
Conversion of Stock, Shares Converted	12,373,247
Debt Instrument, Convertible, Conversion Price	$ 0.2862
Convertible Notes Payable	$ 30,560,080
Amended 2017 Notes [Member] | Series D Convertible Preferred Stock [Member] | Two Thousand And Twenty Notes [Member]
Stock-based compensation:
Conversion of Stock, Shares Converted	9,440,594
Debt Instrument, Convertible, Conversion Price	$ 2.862

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	Jun. 20, 2021	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Mar. 23, 2017
Debt Instrument [Line Items]
Preferred Stock, Par or Stated Value Per Share			$ 0.001
Preferred Stock, Shares Authorized			25,000,000
Voting rights		Holders of shares of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will vote together with the holders of Common Stock as a single class. Each share of Series D Convertible Preferred Stock carries the right to one vote per share. Each share of Series D-1 Convertible Preferred Stock carries the right to 10 votes per share.
Series D Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Shares Authorized		12,374,000	12,374,000
Series D-1 Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Shares Authorized		9,441,000
Firm Commitment [Member]
Debt Instrument [Line Items]
Share Price		$ 0.07
Minimum [Member] | Firm Commitment [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price		0.2862
Maximum [Member] | Firm Commitment [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price		$ 2.862
2017 Financing [Member] | Minimum [Member]
Debt Instrument [Line Items]
Financing arrangement amount					$ 10,000,000
2017 Financing [Member] | Maximum [Member]
Debt Instrument [Line Items]
Financing arrangement amount					$ 20,000,000
2017 Financing [Member]
Debt Instrument [Line Items]
Proceeds from Loans		$ 20,067,000
Proceeds from Related Party Debt		$ 6,770,000
2017 Financing [Member] | Series D and D1 Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Preferred Stock, Convertible, Conversion Price		0.2862
2017 Financing [Member] | Series D Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Par or Stated Value Per Share		0.001
2017 Financing [Member] | Series D-1 Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Par or Stated Value Per Share		0.001
2017 Financing [Member] | Minimum [Member] | Series D and D1 Convertible Preferred Stock [Member] | Final Tranche [Member]
Debt Instrument [Line Items]
Preferred Stock, Convertible, Conversion Price		0.2862
2017 Financing [Member] | Maximum [Member] | Series D and D1 Convertible Preferred Stock [Member] | Final Tranche [Member]
Debt Instrument [Line Items]
Preferred Stock, Convertible, Conversion Price		$ 2.862
2020 Financing [Member]
Debt Instrument [Line Items]
Proceeds from Loans		$ 5,025,000	$ 3,325,000
Proceeds from Related Party Debt		$ 100,000
2020 Financing [Member] | Maximum [Member]
Debt Instrument [Line Items]
Financing arrangement amount				$ 20,000,000
Non-Amended 2017 Notes [Member] | Series D Convertible Preferred Stock [Member] | Two Thousand And Twenty Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 0.2862
Conversion of Stock, Shares Converted	12,373,247
Amended 2017 Notes [Member] | Series D Convertible Preferred Stock [Member] | Two Thousand And Twenty Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 2.862
Conversion of Stock, Shares Converted	9,440,594

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	1 Months Ended
	Apr. 20, 2020	Jun. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Notes Payable		$ 127,393	$ 212,790
Paycheck Protection Program [Member] | The CARES Act [Member]
Short-term Debt [Line Items]
Proceeds from Loans	$ 62,500
Debt Instrument, Description	The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower’s average monthly payroll expenses.

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Related Party Transaction [Line Items]
Accrued Professional Fees	$ 1,368,089		$ 1,368,089		$ 1,175,589
Salary and Wage, Officer, Excluding Cost of Good and Service Sold	96,250	$ 96,250	192,500	$ 192,500
MrBruce Horowitz [Member]
Related Party Transaction [Line Items]
Professional Fees	42,400	$ 11,200	127,200	$ 63,600
Accrued Professional Fees	$ 37,500		$ 37,500		$ 75,000

Summary of Short-term Receivabl

Summary of Short-term Receivables (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Tax Credit	$ 5,408	$ 3,930
Gross receivable	2,104,543	2,104,543
Reserve for uncollectibility	(2,104,543)	(2,104,543)
Net receivable	5,408	3,930
Legal Fees [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Tax Credit
Gross receivable	455,500	455,500
Reserve for uncollectibility	(455,500)	(455,500)
Net receivable
Settlement [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Tax Credit
Gross receivable	1,649,043	1,649,043
Reserve for uncollectibility	(1,649,043)	(1,649,043)
Net receivable
Australian Taxation Office [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Tax Credit	5,408	3,930
Gross receivable
Reserve for uncollectibility
Net receivable	$ 5,408	$ 3,930

Stockholders_ Deficiency (Detai

Stockholders’ Deficiency (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Jun. 20, 2021	Jun. 30, 2021	Jun. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,700,000
Proceeds from Warrant Exercises		$ 250,510	$ 42,640
Series D Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock Issued During Period, Shares, New Issues	12,373,247
Series D-1 Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock Issued During Period, Shares, New Issues	9,440,594
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross		250,000
Stock Issued During Period, Value, Restricted Stock Award, Gross		$ 19,750
Common Stock [Member] | Advisory Board [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross		25,000
Stock Issued During Period, Value, Restricted Stock Award, Gross		$ 1,675
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,700,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.0533
Proceeds from Warrant Exercises		$ 250,510
Warrant [Member] | Advisory Board [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.2862
Proceeds from Warrant Exercises		$ 488

Schedule of Right-of-Use Assets

Schedule of Right-of-Use Assets and Liabilities (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Leases
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 45,784	$ 44,882
Right-of-use assets obtained in exchange for lease obligations: Operating leases
Operating Lease, Weighted Average Remaining Lease Term	1 year	2 years
Operating leases	8.00%	8.00%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payment for Lease (Details)	Jun. 30, 2021USD ($)
Leases
2021	$ 46,687
2022	46,687
Total future minimum lease payments	93,374
Less: amount representing imputed interest	(6,400)
Total	$ 86,974

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)ft²	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)ft²	Jun. 30, 2020USD ($)
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Operating Lease, Payments			$ 45,784	$ 44,882
Research and Development Expense [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Operating Lease, Expense	$ 15,363	$ 14,888	31,871	29,090
General and Administrative Expense [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Operating Lease, Expense	7,681	7,444	15,935	14,544
Property Subject to Operating Lease [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Operating Lease, Expense	$ 23,044	$ 22,332	$ 47,806	$ 43,634
Knoxville Tennessee [Member]
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]
Area of Land | ft²	4,500		4,500
Lessee, Operating Lease, Term of Contract	5 years		5 years
Lease Expiration Date			Jun. 30, 2022
Operating Lease, Payments			$ 7,900

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Aug. 12, 2021	Jun. 30, 2021
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,700,000
Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross		250,000
Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,700,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.0533
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	25,000
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.0533
Series D-1 Convertible Preferred Stock [Member] | Subsequent Event [Member] | Non-related Party Investor [Member]
Subsequent Event [Line Items]
Preferred Stock, Value, Subscriptions	$ 150,000
Preferred Stock, Shares Subscribed but Unissued	52,411